search results for 
Logo

Research and development

Product and process development as well as the improvement of therapies are at the core of our growth strategy. Fresenius focuses its R & D efforts on its core competencies in the following areas:

  • Dialysis
  • Infusion and nutrition therapies
  • Generic IV drugs
  • Medical devices

Apart from new products, we are concentrating on developing optimized or completely new therapies, treatment methods, and services.

Research and development expenses were €348 million (2012: €305 million), approximately 4.6% of our product sales (2012: 4.4%). Fresenius Medical Care increased its R & D spending by 9% and Fresenius Kabi by 29%. This was mainly driven by the first-time consolidation of Fenwal. Detailed figures are included in the segment reporting.

As of December 31, 2013, there were 1,969 employees in research and development (2012: 1,903). Of that number, 583 were employed at Fresenius Medical Care (2012: 550) and 1,386 at Fresenius Kabi (2012: 1,305).

Our main research sites are in Europe, the United States, and India. Product-related development activities are also carried out in China. Our R & D projects are mainly conducted in-house; external research is commissioned only on a limited scale.

KEY FIGURES RESEARCH AND DEVELOPMENT


20132012201120102009
R & D expenses, € in millions348305267244240
as % of product sales4.64.44.34.24.7
R & D employees1,9691,9031,5921,4491,421

20132012201120102009
R & D expenses, € in millions348305267244240
as % of product sales4.64.44.34.24.7
R & D employees1,9691,9031,5921,4491,421

Continue reading:
Fresenius Medical Care

QUICKFINDER

History

My Annual report

Tools